Human tissue factor pathway inhibitor-2 (TFPI-2) is a Kunitz-type serine protease inhibitor that inhibits plasmin, trypsin, chymotrypsin, cathepsin G, and plasma kallikrein but not urokinase-type plasminogen activator, tissue plasminogen activator, or thrombin. Preliminary ®ndings in our laboratory suggested that the expression of TFPI-2 is downregulated or lost during tumor progression in human gliomas. To investigate the role of TFPI-2 in the invasiveness of brain tumors, we stably transfected the human high-grade glioma cell line SNB19 and the human low-grade glioma cell line Hs683 with a vector capable of expressing a transcript complementary to the full-length TFPI-2 mRNA in either sense (0.7 kb) or antisense (1 kb) orientations. Parental cells and stably transfected cell lines were analysed for TFPI-2 protein by Western blotting and for TFPI-2 mRNA by Northern blotting. The levels of TFPI-2 protein and mRNA were higher in the sense clones (SNB19) and decreased in the antisense (Hs683) clones than in the corresponding parental and vector controls. In spheroid and matrigel invasion assays, the SNB19 parental cells were highly invasive, but the sense-transfected SNB-19 clones were much less invasive; the antisense-transfected Hs683 clones were more invasive than their parental and vector controls. After intracerebral injection in mice, the sensetransfected SNB19 clones were less able to form tumors than were their parental and vector controls, and the antisense-Hs683 clones but not the parental or vector controls formed small tumors. This is the ®rst study to demonstrate that down-or upregulation of TFPI-2 plays a signi®cant role in the invasive behavior of human gliomas. Oncogene (2001) 20, 6938 ± 6945.
Human tissue factor pathway inhibitor-2 (TFPI-2) is a Kunitz-type serine protease inhibitor that inhibits plasmin, trypsin, chymotrypsin, cathepsin G, and plasma kallikrein but not urokinase-type plasminogen activator, tissue plasminogen activator, or thrombin. Preliminary ®ndings in our laboratory suggested that the expression of TFPI-2 is downregulated or lost during tumor progression in human gliomas. To investigate the role of TFPI-2 in the invasiveness of brain tumors, we stably transfected the human high-grade glioma cell line SNB19 and the human low-grade glioma cell line Hs683 with a vector capable of expressing a transcript complementary to the full-length TFPI-2 mRNA in either sense (0.7 kb) or antisense (1 kb) orientations. Parental cells and stably transfected cell lines were analysed for TFPI-2 protein by Western blotting and for TFPI-2 mRNA by Northern blotting. The levels of TFPI-2 protein and mRNA were higher in the sense clones (SNB19) and decreased in the antisense (Hs683) clones than in the corresponding parental and vector controls. In spheroid and matrigel invasion assays, the SNB19 parental cells were highly invasive, but the sense-transfected SNB-19 clones were much less invasive; the antisense-transfected Hs683 clones were more invasive than their parental and vector controls. After intracerebral injection in mice, the sensetransfected SNB19 clones were less able to form tumors than were their parental and vector controls, and theIntroduction Malignant brain tumors are characterized by the invasive in®ltration and destruction of surrounding normal brain tissue; their invasive behavior seems to depend in part on a variety of proteolytic enzymes including serine, metallo-, and cysteine proteases. (Duy, 1992) . Expressed amounts of urokinase-type plasminogen activator (uPA) and uPA receptors (uPAR) in particular correlate directly with the invasiveness of human gliomas (Yamamoto et al., 1994; Gladson et al., 1995) . Receptor-bound uPA converts the zymogen plasminogen to plasmin, a broad-spectrum serine protease that promotes lysis and dissolution of the extracellular matrix (ECM) and promotes tumor cell invasion (Mignatti and Rifkin, 1993; Murphy et al., 1992; Vassalli et al., 1985; Kwaan, 1992; Kramer et al., 1994) . Inhibitors of plasmin probably play a role in the regulation of the invasive and malignant behavior of gliomas.
Tissue factor pathway inhibitor-2 (TFPI-2), also called matrix-associated serine protease inhibitor (MSPI) and placental protein 5 (PP5), is a novel 32 ± 33-kDa serine protease inhibitor (Sprecher et al., 1994; Rao et al., 1996; Miyagi et al., 1994a ) that consists of three Kunitz-type proteinase inhibitor domains homologous to TFPI. Most (75 ± 90%) of the TFPI-2 triplet is associated with the ECM (Iino et al., 1998) . This triplet is synthesized from a 25-kDa non-glycosylated protein by means of dierential glycosylation (Rao et al., 1996) . TFPI-2 inhibits trypsin, plasmin, chymotrypsin, cathepsin G, plasma kallikrein and factor VIIa-tissue factor complex but not uPA, tissue plasminogen activator (tPA), or thrombin (Sprecher et al., 1994; Rao et al., 1995a,b,c; Petersen et al., 1996) . The TFPI-2 gene has been mapped to chromosome 7q22 by¯uoresence in situ hybridization (Miyagi et al., 1996b) . Recombinant TFPI-2 inhibited plasmin, regardless of whether the enzyme was associated with tumor cells or with ECM, and inhibited matrix degradation and Matrigel invasion by HT-1080 ®brosarcoma cells (Rao et al., 1998) .
Our ®ndings suggested that TFPI-2 expression dier among glioma cell types according to grade, with higher-grade cells no expression of TFPI-2 and low grade cells with higher expression and also signi®cantly very low levels of TFPI-2 during the progression of human gliomas . For the study reported here, we chose a high-grade and a low-grade glioma cell line (SNB19 and Hs683, respectively) and stably transfected them with a vector capable of expressing a transcript complementary to the fulllength TFPI-2 mRNA in either sense (0.7 kb) or antisense (1 kb) orientation. We then selected sense clones (SNB19 cells) that expressed high levels of protein and message and antisense clones (Hs683 cells) that expressed low levels of protein and message relative to their parental-cells and only vector transfected controls. We observed both in vitro and in vivo models that the upregulation or downregulation of TFPI-2 caused decreased or increased invasive behavior of these clones compared to their parental and vector controls.
Results
We used the eukaryotic expression vector pcDNA 3.1 to transfect SNB19 (high-grade glioma) cells with a 0.7-kb sense TFPI-2 cDNA and Hs683 (low-grade glioma) cells with a 1-kb antisense TFPI-2 construct. Stable transfectants were selected with cloning cylinders after 10 ± 15 days and weaned from the selection medium. Clones were initially selected in 800 mg/ml of G418. Not much dierences in growth rate were found among the parental cells, cells transfected with the vector only, the SNB19 sense transfectants, and the Hs683 antisense transfectants. We developed several sense and antisense clones, which have similar expression levels.
TFPI-2 protein expression
ECM proteins obtained from 80 ± 90% con¯uent cultures of these cells were subjected to SDS ± PAGE and analysed for TFPI-2 protein by Western blotting with anti TFPI-2 polyclonal antibody. As expected, prominent TFPI-2 triplet bands were observed from the SNB19-sense transfectants but not from the parental and vector transfectant SNB19 clones ( Figure  1a ) and signi®cantly reduced levels were observed in antisense clones (Hs683) compared to parental and vector controls (Figure 1b ).
TFPI-2 mRNA expression
Northern blot analysis of the same transfectants and controls con®rmed that the SNB19-sense transfectants overexpressed TFPI-2 message (Figure 2a) , and the SNB19 parental and vector-only cells expressed no TFPI-2 mRNA. It (Figure 2b ) clearly shows several fold reduction in mRNA message in antisense clones (Hs683). GAPDH was used as an internal control.
Cell invasiveness in matrigel
The staining of SNB19-sense clones that invaded through the transwell inserts precoated with matrigel was considerably less intense than were the SNB19 parental and vector controls (Figure 3a) . The MTT assay showed that 42 and 45% of parental and vector controls that invaded the matrigel signi®cantly higher (P50.001) compared to 13 to 16% in SNB19-sense clones (Figure 3b ). The staining of Hs683-antisense clones that invaded through the transwell inserts precoated with matrigel were more intense than were the corresponding parental and vector controls ( Figure  3c ). The MTT assay showed that 10 and 12% of parental and vector controls that invaded the matrigel signi®cantly less (P50.001) compared to 30 ± 35% in Hs683 antisense clones (Figure 3d ).
Migration assay
We measured migration of the two transfectants and their controls from spheroids of the same cell type. Considerably less number of cell migration was observed from the SNB19-sense spheroids than from the SNB19 parental spheroids and vector spheroids ( Figure 4a ) and the quantitative analysis demonstrated that the migration of cells was signi®cantly inhibited Figure 1 Western blot analysis of TFPI-2 expression in SNB19 parental cells, SNB19 cells transfected with vector only, and SNB19 cells transfected with a TFPI-2 sense construct (a) and in Hs683 parental, vector controls, and antisense-TFPI-2 clones (b). Human anti-TFPI-2 polyclonal antibody was used as described in Materials and methods
Figure 2
Northern blot analysis of TFPI-2 mRNA in SNB19 parental cells, SNB19 cells transfected with vector only, and SNB19 cells transfected with a TFPI-2 sense fragment (a) and Hs683 parental, vector controls, and antisense-TFPI-2 clones (b). Total cellular RNA was extracted and 10-mg portions were electrophoresed in agarose-formaldehyde gels and then transferred to a nylon membrane and labeled with 32 P-TFPI-2 cDNA. The membranes were then stripped and rehybridized with GAPDH cDNA as an internal control (P50.001) in SNB19-sense spheroids compared to parental and vector spheroids ( Figure 4b ). Considerably more Hs683-antisense transfectants migrated than did their parental and vector controls ( Figure 4c ) and the quantitative analysis showed that the migration of cells were signi®cantly more (P50.001) in Hs683 antisense transfectants compared to parental and vector controls (Figure 4d ).
Glioma spheroid invasiveness into rat-brain aggregates
Fetal rat brain cell aggregates were confronted with spheroids consisting of either parental cells, vector controls of SNB19 and Hs683, sense clones (SNB19), or antisense clones (Hs683) in an in vitro model of invasion (spheroid assay). Spheroids consisting of the SNB19 TFPI-2-sense clones failed to invade the fetal rat brain aggregates, although spheroids of parental cells or vector control cells did ( Figure 5a ). In contrast, spheroids from the Hs683 TFPI-2-antisense clones did invade the fetal rat brain aggregates, but the spheroids of parental and vector controls did not (Figure 5b ). Quantitative analysis of the remaining fetal rat brain aggregates were 10 ± 15% in SNB19 parental and vector clones when compared to 80 ± 85% in SNB19 sense clones (Figure 5c ). In contrast 85 ± 90% rat brain aggregates remained in Hs683 parental and vector clones compared to 40 ± 50% in Hs683 antisense clones ( Figure 5c ). The invasiveness of fetal rat brain aggregates signi®cantly decreased in sense SNB19 clones compared to parental, vector and transfected clones, in contrast to signi®cantly increased invasiveness of fetal rat brain aggregates in Hs683 antisense clones compared to parental and vector transfected clones (P50.001).
Intracerebral tumor formation in athymic mice
As expected, mice injected intracerebrally with the SNB19 high-grade glioma cells (or the vector controls) formed brain tumors; those injected with the SNB19-sense transfectants formed smaller tumors (Figure 5d ). On the other hand, injection of the Hs683 low-grade glioma cells (parental cells and vector-controls) produced no tumors, as is typical of this cell line. However, very small tumors (approximately 1 ± 2 mm or less in few cases) formed in the mice that had been injected with the Hs683 TFPI-2-antisense clones (data not shown). The sections analysed using H & E staining and blindly reviewed by a neuropathologist revealed that there was no signi®cant dierence in tumor size in mice injected with SNB19 parental and vector transfected clones. But the tumor size was signi®cantly reduced (P50.001) in SNB19 sense clones compared to parental and vector clones (Figure 5e ).
Discussion
Human TFPI-2 is a 32-kDa Kunitz-type inhibitor present in the ECM of endothelial cells (Iino et al., 1998) and ®broblasts (Rao et al., 1995b) . TFPI-2 transcripts are abundant in the full-term placenta and are also widely expressed in various adult human tissues, such as liver, skeletal muscle, heart, kidney, and pancreas (Miyagi et al., 1994a) . The broad distribution of TFPI-2 mRNA suggests that, like TFPI-2 may participate in blood coagulation. Several ovarian carcinoma cell lines, and the T98G human glioma cell line, also contain signi®cant amounts of the transcript (Miyagi et al., 1994a) . We chose the Hs683 low-grade glioma cell line for the present study because of its relatively noninvasive nature, and it produces high levels of TFPI-2 protein and mRNA. Similarly, we chose the SNB19 glioblastoma cell line for its highly invasive and tumor-forming characteristics, as well as its relative de®ciency in producing TFPI-2 protein and mRNA. In the present study, we were able to overexpress the TFPI-2 protein and mRNA by transfecting SNB19 cells with a TFPI-2 sense construct; similarly, we were able to reduce the expression of TFPI-2 protein and mRNA in Hs683 cells by transfecting them with an antisense-TFPI-2 construct. The mechanism by which the sense and antisense constructs aected the expression of TFPI-2 in the transfected cells is unclear; possibly they may have interfered with mRNA transport or hybridized with cytoplasmic TFPI-2 mRNA, which presumably would interfere with translation.
Many tumor cells secrete polypeptides such as proteases; proteases and their inhibitors are known to be involved in the invasive growth of tumor cells Umenishi et al., 1990; Yasumitsu et al., 1992) . Some human cancer cell lines secrete serine proteinases, including trypsin (Koshikawa et al., , 1994 and multiple forms of trypsin inhibitors. As an ECM-associated serine protease inhibitor (Rao et al., 1996) . A previous study of recombinant TFPI-2 showed that TFPI-2 inhibited the generation of plasmin at the surfaces of ECM and HT-1080 ®brosarcoma cells and inhibited the degradation and invasion of matrix by these cells (Rao et al., 1998) . TFPI-2 directly inhibits plasmin, thereby releasing growth factors from ECM and activating transforming growth factor b and certain pro-MMPs by tumor cells, which causes degradation of ECM followed by invasion (Kwaan, 1992; Rao et al., 1999) . One of the possible reasons might be that over expression of TFPI-2 is blocking the plasmin activation, therefore ECM is not destructed even though high levels of uPA, tPA and thrombin are present. No natural plasmin inhibitors have been identi®ed that inhibits cell-surface plasmin. Plasmin bound to the tumor cells is not accessible to inhibition by a2-antiplasmin, a known plasma plasmin inhibitor (Eitzman et al., 1996; Stephens et al., 1989; Bizik et al., 1990; Quax et al., 1991; Reinartz et al., 1993) . Among other natural serine protease inhibitors, protease nexin-1 primarily inhibits a-thrombin as does plasmin on the cell surface (Wagner et al., 1989) . Maspin (mammary serine protease inhibitor), a tumor suppressor protein, (Zou et al., 1994 ) may or may not inhibit proteases; the high homology to serpins, some of which can inhibit proteases (e.g., a2-antitrypsin, PAI-1, and PAI-2) and some of which cannot (e.g., ovalbumin, angiotensinogen), may explain the controversy (Pemberton et al., 1995) . One study that attributed protease inhibition to maspin found that maspin inhibited tPA but not uPA or plasmin . It was found that maspin suppressed the invasive phenotype in MDA-MB-435 cells by altering their integrin pro®les (Seftor et al., 1998) . Other studies have implicated the tissue factor VIIa complex in the promotion of tumor progression (Dvorak, 1987; Ruf and Mueller, 1996; Shoji et al., 1998) . Speci®cally, tissue factor eects on tumor angiogenesis and metastasis required it to be in complex with the catalytically active factor VIIa (Ollivier et al., 1998) . As noted above, TFPI-2 inhibits the tissue factor VIIa complex (Sprecher et al., 1994; Dvorak, 1987) . Tissue factor also upregulated the production of vascular endothelial cell growth factor (Ollivier et al., 1998) and uPAR (Taniguchi et al., 1998) in tumor cells, and its levels perfectly correlated with the degree of tumor angiogenesis and progression in ®brosarcomas, melanomas, breast and pancreatic tumors (Contrino et al., 1996; Mueller et al., 1992; Nakagawa et al., 1998; Mueller and Ruf, 1998) . Recently it was reported (Neaud et al., 2000) that human liver myo®broblasts promote in vitro invasion of human hepatocellular carcinoma (HCC) cells through a hepatocyte growth factor (HGF)/urokinase/plasmin-dependent mechanism. Myo®broblasts also synthesize the serine proteinase inhibitor tissue factor pathway inhibitor-2 (TFPI-2). Despite the fact that recombinant TFPI-2 readily inhibits plasmin, it has been shown that it potentiates HGF-induced invasion of HCC cells and is capable of inducing invasion on its own. Furthermore, HCC cells stably transfected with a TFPI-2 expression vector became spontaneously invasive. HCC cells express tissue factor and speci®cally factor VII. Addition of an antibody to factor VII abolished the pro-invasive eect of TFPI-2. It was suggested that TFPI-2 induces invasion following binding to a tissue factor/factor VIIa complex preformed on HCC cells. It may be speci®c for liver tumor cells. Our recent studies demonstrated the aect of TFPI-2 in vitro in other cancers like prostate cancer cell line (LNCaP) and amelanotic melanomas (C-32) and lung cancer cell line (A549) . Recently it was reported that antiproliferative activity of TFPI is mediated by the VLDL receptor and suggest that this receptor-ligand system may be a useful target for the development of new antiangiogenic and antitumor agents (Hembrough et al., 2001) . In the present study, transfecting SNB19 cells with a sense-TFPI-2 cDNA construct inhibited cell migration and invasiveness in vitro and reduced tumor formation in vivo, but transfecting low-grade Hs683 cells with antisense-TFPI-2 enhanced migration and invasiveness in vitro and very small tumor formation in vivo (Figures 3, 4 and 5) . On the basis of these ®ndings, we believe that TFPI-2 interferes with the promotion of glioma progression in vivo. We are con®dent that our multifaceted (antisense and sense) approach elucidated the role of TFPI-2 in gliomas both in vitro and in vivo, and that these ®ndings will be replicated in further studies to determine the regulatory role of this novel inhibitor in extracranial neoplasms and other tumors. To our knowledge, this is the ®rst study that TFPI-2 is down regulated in gliomas. We observed similar aect of TFPI-2 in vitro in other cancers like prostate cancer cell line (LNCaP) ) and amelanotic melanomas (C-32) and lung cancer cell line (H1299) .
Materials and methods

Cell culture
High-grade human glioblastoma cells (SNB19) and low-grade human glioma cells (Hs683) were obtained from the American Type culture collection (Manassas, VA, USA) and were grown in Dulbecco's Modi®ed Eagle's Medium (DMEM) supplemented with 1% glutamine, 100 mg/ml streptomycin, 100 U/ml penicillin, and 10% fetal bovine serum (pH 7.2 ± 7.4) in a humidi®ed atmosphere containing 5% CO 2 at 378C. Subcultures were taken every 3 ± 5 days.
Preparation of constructs
One-kb and 0.7-kb fragments of human TFPI-2 were ampli®ed by reverse transcriptase-polymerase chain reaction (RT ± PCR) using speci®c primers. The 0.7-kb fragment was sub cloned in the sense orientation and the 1-kb fragment in the antisense orientation into the pcDNA 3.1 vector (Invitrogen, San Diego, CA, USA). The orientation of the fragments was con®rmed by restriction digestion, and subsequent sequencing with an automated sequencer (Applied Biosystems Inc., USA) showed 100% homology with the published sequence of TFPI-2 cDNA (Sprecher et al., 1994) .
Transfection of cells with TFPI-2
SNB19 cells were transfected with the 0.7-kb (sense) cDNA construct, and Hs683 cells were transfected with the 1-kb (antisense) construct; both cell types were also transfected with the pcDNA3.1 vector alone (as a control) by using Lipofectamine (Life Technologies, Gaithersburg, MD, USA). Cells were grown overnight (4610 5 cells per 60-mm dish), washed with phosphate-buered saline (PBS), and treated with 1 ± 2 mg of plasmid DNA in 100 ml of serum-free medium. Lipofectamine (7 ml diluted in 100 ml of serum-free medium) was added drop-wise to the DNA. Twelve hours later, the medium was replaced with DMEM containing 10% fetal bovine serum. Selection was begun 48 h after transfection by growing the cells in complete medium containing G418 (800 mg/ml; Life Technologies). Every 3 or 4 days, transfected cells were passaged. They were always grown in the presence of G418. Intermittently we checked the selected clones were checked by Western and Northern blots for the presence of TFPI-2 expression. Selected stable transfectants were expanded and used for study.
Western blotting
Parental cells, vector controls and sense and antisense clones (TFPI-2 cDNA transfectant stable cell lines) were grown to 80 ± 90% con¯uence in six-well tissue culture plates. The ECM was prepared (Ehrlich et al., 1991) by lysing the cells with Triton X-100. Brie¯y, cells were washed three times with PBS and then lysed through incubation with PBS containing 0.5% (v/v) Triton X-100 for 20 min at room temperature. The remaining ECM was washed three times with PBS and another three times with 20 nM Tris-HCl, pH 7.4, containing 100 mM NaCl and 0.1% (v/v) Tween-20. After these washings no visible cells were left in the dishes as judged by light microscopy. To collect the ECM proteins, 200 ml of 16SDS-polyacrylamide gel electrophoresis (PAGE) sample buer was added to each six well and agitated for 15 ± 20 min at room temperature from the transfected cells (sense [SNB19], antisense [Hs683] , and vector-alone) and from the parental cells, 25-ml aliquots of these extracts were assayed for TFPI-2 triplet levels by Western blotting as follows. ECM samples were boiled for 3 min, and proteins were separated by SDS ± PAGE using 12 or 15% polyacrylamide gels (Laemmli, 1970) . After electrophoresis, proteins were electro blotted onto nitrocellulose membranes (Towbin et al., 1979) and blocked with 4% nonfat dry milk in 10 mM Tris-HCl, 150 mM NaCl, pH 7.4, and 0.1% Tween-20 (TTBS) for 2 h at 238C. The membranes were then incubated overnight at 48C with anti-TFPI-2 antibody that had been diluted 1 : 3000 in TTBS containing 1% bovine serum albumin. After several washes, the membranes were incubated for 1 h with a peroxidase-conjugated secondary antibody (also diluted 1 : 3000 in TTBS and 1% bovine serum albumin). The immunoreactive proteins were identi®ed by using an enhanced chemiluminescence (ECL) reagent system according to the manufacturer's instructions (Amersham).
Northern blotting
Steady-state levels of TFPI-2 mRNA were measured by Northern blot analysis. Total cellular RNA was extracted as described previously (Chomczynski and Sacchi, 1987) and 10 mg of the RNA was electrophoresed in agarose-formaldehyde gel, transferred to a nylon membrane by capillary action overnight, and then cross-linked with UV irradiation. The membranes were hybridized at 658C overnight with a TFPI-2 cDNA probe labeled with 32 P-deoxycytidine triphosphate by random primer labeling, after which they were washed in 0.5% SSC and 0.1% SDS for 20 min at room temperature, then for 15 min at 658C, and then exposed to X-ray ®lm at 7708C. The membranes were then stripped and rehybridized with glyceraldehyde phosphate dehydrogenase (GAPDH) cDNA as an internal control.
Matrigel invasion assay
The invasiveness of the transfected cells (SNB19 sense, Hs683 antisense, and vector-only) and the parental cells was tested in vitro in a matrigel invasion assay. Brie¯y, transwell inserts with 8-mm pores were coated with matrigel (1 mg/ml), and then cells were trypsinized and 20 ml of the cell suspension (3610 5 cells/ml) was added to triplicate wells. After incubation for 24 h at 378C, cells that passed through the ®lters into the lower wells were quanti®ed and expressed as a percentage of the sum of the cells in the upper and lower wells. Cells on the lower side of the membrane were ®xed, stained with Hema-3, and photographed.
Migration assay
Parental cells and transfected cells (SNB19 sense, Hs683 antisense, and vector-only clones, 3610 6 cells per plate) were cultured to form spheroids in 100-mm 2 tissue culture plates precoated with 0.75% agar as described elsewhere (LundJohansen et al., 1990) . The spheroids were stained with thē uorescent dye DiI (Molecular Probes Inc, Eugene, OR, USA) and explanted onto a plastic surface; 24 h later, the area covered by tumor cells that had migrated from the spheroids was measured using a microscope calibrated with a stage and ocular micrometer and used as an index of cell migration.
Three-dimensional spheroid invasion assay
The invasiveness of glioma spheroids was measured in a 3-dimensional model (Pedersen et al., 1993) in which the spheroids were stained with DiI and cultured with fetal rat brain aggregates stained with DiO. At various culture intervals, serial 1-mm optical sections were obtained with the aid of a confocal laser scanning microscope from the surface to center of the co cultures. DiI and DiO¯uorescence (Molecular Probes Inc, Eugene, OR, USA) were detected with an argon laser at 488 nm with a band pass ®lter at 520 ± 560 nm (DiI) and a helium/neon laser at 543 nm with a long pass ®lter at 590 nm (DiO). The remaining volume of the brain aggregate or tumor spheroid during co cultures at 24, 48 and 72 h was quantitated as described previously (Kondraganti et al., 2000) .
Intracerebral injection
To examine the in vivo eects of the up regulation or down regulation of TFPI-2 produced by the transfection, we injected suspensions of each cell type into the brains of athymic mice. A total of 40 mice were used, ®ve each for the parental or vector-control conditions and 10 each for the two transfectant conditions. Cells were trypsinized and resuspended in serum-free medium to a concentration of 2610 5 cells/ml. The mice were anesthetized with an i.p. injection of a 0.35 ± 0.45 ml solution consisting of 0.06 M 2,2,2-tribromethanol (Aldrich Chemical Co., Milwaukee, WI, USA), 1.25 isoamyl alcohol and 98.5% bacteristatic saline and injected intracerebrally with a 10-ml aliquot (2610 5 cells/ml) of the speci®ed cell type with the aid of a stereotactic frame as described elsewhere . Four weeks later, the mice were killed by intracardiac perfusion, ®rst with PBS and then with 4% paraformaldehyde in normal saline. The brains were removed, placed in 4% paraformaldehyde for 4 h, and then incubated for 2 days in 30% sucrose in PBS at 48C. The following day, the brains were cut, embedded in microscopic slides, and frozen at 7208C. Cryostat sections were stained with hematoxylin and eosin to examine tumor growth. The sections were blindly reviewed by a neuropathologist and scored for the size of the tumor in each case semiquantitatively. The maximal cross sectional diameter measured in sections of each tumor taken as a measurement of tumor size and compared between controls and sense transfectants. The variation between the sections in each group was less than 10%.
Abbreviations ECM, extracellular matrix; uPA, urokinase-type plasminogen activator; uPAR, uPA receptor; tPA, tissue type plasminogen activator; PAI-1, plasminogen activator inhibitor-1; PMA, phorbol 12 myristate 13-acetate; mTFPI-2, recombinant trypsin/tissue factor pathway inhibitor-2
